<DOC>
	<DOCNO>NCT02770222</DOCNO>
	<brief_summary>The primary objective 2-part drug interaction study follow : - To evaluate effect gemfibrozil pharmacokinetics ( i.e. , amount blood ) selexipag metabolite ACT-333679 ( Part I ) . - To evaluate effect rifampicin pharmacokinetics selexipag metabolite ACT-333679 ( Part II ) .</brief_summary>
	<brief_title>A Clinical Study Investigate Effect Gemfibrozil Rifampicin Blood Concentrations Selexipag Healthy Subjects</brief_title>
	<detailed_description>Because non-clinical study show selexipag active metabolite , ACT-333679 , substrates cytochrome P450 2C8 ( CYP2C8 ) , present clinical study aim investigate effect strong inhibitor ( gemfibrozil ) moderate inducer ( rifampicin ) CYP2C8 pharmacokinetic selexipag ACT-333679 recommend FDA 's Guidance Industry Drug Interaction Studies ( FDA , 2012 ) .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Signed informed consent form . Male subject age 18 55 year ( inclusive ) screening . Body mass index 18.0 28.0 kg/m2 ( inclusive ) screening . Healthy basis physical examination , cardiovascular assessment laboratory test screen . Any contraindication gemfibrozil rifampicin treatment . History clinical evidence disease and/or existence surgical medical condition , might put subject risk participation study interfere absorption , distribution , metabolism excretion study treatment . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>